Navigation Links
Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
Date:12/12/2007

SAN CARLOS, Calif., Dec. 12 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced dosing of the first patient in a Phase 2 proof-of-concept trial of alfimeprase for the treatment of acute ischemic stroke.

Nuvelo has also been granted fast track designation by the U.S. Food and Drug Administration (FDA) for alfimeprase in this indication. Fast track designation, which was mandated by the FDA Modernization Act of 1997, can potentially facilitate expedited review of a Biologics License Application (BLA). Fast track designation is reserved for new drugs that demonstrate the potential to address an unmet medical need and are intended for the treatment of a serious or life-threatening condition.

The Phase 2 CARNEROS-1 (Catheter Directed Alfimeprase for Restoration of Neurologic Function and Rapid Opening of Arteries in Stroke) proof-of-concept trial is a multi-center, open-label, two part, dose escalation (1 mg, 5 mg and 10 mg) study that will enroll approximately 100 patients within 3-9 hours of stroke onset. CARNEROS-1 is designed to evaluate the safety and efficacy of intra-arterial, catheter-directed, bolus alfimeprase. The primary efficacy endpoint is recanalization, or unblocking, of the primary arterial occlusive lesion within 120 minutes of treatment with alfimeprase. Safety will be assessed, including the rate of symptomatic intracerebral hemorrhages at 24 hours.

"We believe that a safer, more efficacious intra-arterial therapy can change the treatment paradigm for stroke patients and that a product candidate such as alfimeprase holds the potential to restore flow rapidly and expand the current treatment window for this underserved patient population," said Michael Levy, M.D., executive vice preside
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
2. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
3. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
4. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
5. Enrollment Begins on Human PK Study for Medidur(TM) FA
6. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
7. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
10. DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 22, 2014  - ... Today Lincor announced general availability of MediaLINC ... delivers a range of education, entertainment and clinical content ... (Logo: http://photos.prnewswire.com/prnh/20140822/702945) , " Lincor ... care patient engagement to bedside smart devices, " comments ...
(Date:8/22/2014)... Aug. 22, 2014  Cannabis Science, Inc. (OTC: ... drug development and related consulting, is pleased to ... medical cannabis conference taking place at the Faculty ... , on October 22, 2014.  The multilingual conference ... as researchers, health professionals, and patients, to discuss ...
(Date:8/22/2014)... Aug. 22, 2014  Landauer, Inc. (NYSE: ... radiation measurement and monitoring, outsourced medical physics services and ... William E. Saxelby , its President and Chief Executive ... Executive Officer and as a member of the Board ... will be replaced on an interim basis by ...
Breaking Medicine Technology:Lincor Unveils Next Generation TV-based Patient Engagement Solution 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3Landauer, Inc. Announces Executive Management Change 2
... 15, 2011 PDI, Inc. (Nasdaq: ... promotional outsource services to established and emerging health care ... partnership with Qforma, the leading provider of advanced analytics ... Through this agreement, PDI will gain access ...
... REDWOOD CITY, Calif., March 15, 2011 – Ingenuity® ... solutions for life science researchers, today announced new ... in IPA®. Processed RNA-Seq datasets can now be ... context of pathways and diseases for a rich ...
Cached Medicine Technology:PDI Announces Exclusive Partnership With Qforma, Leading Provider of Advanced Analytics for Health Sciences Industry 2Ingenuity Announces RNA-Sequencing Workflow Support and First-of-Its-Kind microRNA Filtering Capability With Latest Release of IPA 2Ingenuity Announces RNA-Sequencing Workflow Support and First-of-Its-Kind microRNA Filtering Capability With Latest Release of IPA 3
(Date:8/22/2014)... The ALS Association, along with its Western Pennsylvania ... Health Network as a Certified Treatment Center of ... (AGH), is the only ALS treatment program in western ... highest levels of established national standards of care in ... to as Lou Gehrig’s Disease. , Allegheny Health Network’ ...
(Date:8/22/2014)... This funding was made through an additional ... Therapeutics, Inc. in the form of a convertible promissory ... collaborate with Saneron on several fronts to enable the ... to regenerative therapies using cord blood to ... Chairman and Co-CEO of Cryo-Cell, stated. He continued, ...
(Date:8/22/2014)... Human induced pluripotent stem cells (hiPSCs) have ... they can be coaxed to turn into specific cells; ... They sometimes mutate, develop into tumors or produce other ... published in STEM CELLS Translational Medicine, researchers appear to ... the material used to reprogram the stem cell after ...
(Date:8/22/2014)... 22, 2014 The New Jersey ... Rutgers, the State University of New Jersey has joined ... media organization, to educate young people about health and ... the strengths of both organizations. , The partnership will ... communications fellowship program, and video communications. ChopChop Magazine ...
(Date:8/22/2014)... air in American cities is getting safer to breathe, ... progress has been made in reducing levels of harmful ... said in a news release. Since 1990, there ... from human sources such as coal-fired plants, a 66 ... in lead, which harms brain development in children. ...
Breaking Medicine News(10 mins):Health News:Allegheny Health Network ALS Program Named Certified Treatment Center of Excellence 2Health News:Allegheny Health Network ALS Program Named Certified Treatment Center of Excellence 3Health News:Cryo-Cell Provides Funding for Cord Blood Clinical Trial Application to Treat ALS 2Health News:Cryo-Cell Provides Funding for Cord Blood Clinical Trial Application to Treat ALS 3Health News:Removing Programming Material After Inducing Stem Cells Could Improve Their Regeneration Ability 2Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 2Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 3Health News:Air in U.S. Cities Getting Cleaner, EPA Says 2
... Reporter , MONDAY, March 26 (HealthDay News) -- Here,s a ... who eat chocolate regularly are somewhat skinnier than folks who ... that chowing down on chocolate will melt off your excess ... modest difference in body mass, or it might be a ...
... honored with the Distinguished Sonographer Award during the 2012 ... at the JW Marriott Desert Ridge Resort and Spa ... Sonographer Award is a means of recognizing and honoring ... to the growth and development of medical ultrasound. ...
... Lisa Esposito HealthDay Reporter , THURSDAY, March ... initiative since the Medicare and Medicaid programs of the ... presidency, is about to face its biggest challenge. ... unprecedented six hours of arguments over three days on ...
... , MONDAY, March 26 (HealthDay News) -- ... leading cause of death among women in the United ... clinics, a new study suggests. Researchers from ... that heart screenings performed during visits to obstetrician/gynecologists could ...
... cancer researcher Professor Jane Visavader has been selected to ... The fellowship recognises Professor Visvader,s research over the past ... that can give rise to all types of cells ... which different types of breast cancer arise., Professor Visvader, ...
... offering in late March a new stereotactic radiosurgery ... available. The new imaging and radiosurgery ... fast and precise noninvasive image-guided radiation therapy. Radiosurgery ... with high precision to a tumor. "Radiosurgery ...
Cached Medicine News:Health News:Does Chocolate Help You Stay Slim? 2Health News:Does Chocolate Help You Stay Slim? 3Health News:Supreme Court Prepares to Tackle Affordable Care Act 2Health News:Supreme Court Prepares to Tackle Affordable Care Act 3Health News:Supreme Court Prepares to Tackle Affordable Care Act 4Health News:Supreme Court Prepares to Tackle Affordable Care Act 5Health News:Supreme Court Prepares to Tackle Affordable Care Act 6Health News:Ob/Gyn Visit a Good Time to Screen for Heart Disease: Study 2Health News:Professor Jane Visvader elected to Australian Academy of Science 2Health News:Cancer treatment system sculpts radiation beam to match shape of a tumor 2
... key challenges. Reducing costs while adjusting to ... Meeting ever-increasing expectations from more informed customers. ... with labor shortages. Providing value in managing ... theres targeted relief from a trusted partner ...
... The Roche Diagnostics Task Targeted ... state-of-the-art automation of pre- ... laboratories: decapping, sorting / archiving ... into bar code labeled secondary ...
... 20 years of experience in providing ... Life Sciences, the Freedom EVO platform ... for expansion according to future needs., ... Freedom EVOware, each system is equipped ...
... designed a flexible liquid handling system that ... three liquid handlers all on the same ... for targeted applications or custom-tailored to meet ... provide comprehensive systems that combine all the ...
Medicine Products: